Target Name: TRDC
NCBI ID: G28526
Review Report on TRDC Target / Biomarker Content of Review Report on TRDC Target / Biomarker
TRDC
Other Name(s): T cell receptor delta constant | TCRD

TRDC as a Potential Drug Target: Unlocking the Power of T Cells

The immune system is the body's first line of defense against external threats, and it is crucial for maintaining a healthy balance of

Protein Name: T Cell Receptor Delta Constant

Functions: Constant region of T cell receptor (TR) delta chain that participates in the antigen recognition (PubMed:24600447). Gamma-delta TRs recognize a variety of self and foreign non-peptide antigens frequently expressed at the epithelial boundaries between the host and external environment, including endogenous lipids presented by MH-like protein CD1D and phosphoantigens presented by butyrophilin-like molecule BTN3A1. Upon antigen recognition induces rapid, innate-like immune responses involved in pathogen clearance and tissue repair (PubMed:28920588, PubMed:23348415). Binding of gamma-delta TR complex to antigen triggers phosphorylation of immunoreceptor tyrosine-based activation motifs (ITAMs) in the CD3 chains by the LCK and FYN kinases, allowing the recruitment, phosphorylation, and activation of ZAP70 that facilitates phosphorylation of the scaffolding proteins LCP2 and LAT. This lead to the formation of a supramolecular signalosome that recruits the phospholipase PLCG1, resulting in calcium mobilization and ERK activation, ultimately leading to T cell expansion and differentiation into effector cells (PubMed:25674089). Gamma-delta TRs are produced through somatic rearrangement of a limited repertoire of variable (V), diversity (D), and joining (J) genes. The potential diversity of gamma-delta TRs is conferred by the unique ability to rearrange (D) genes in tandem and to utilize all three reading frames. The combinatorial diversity is considerably increased by the sequence exonuclease trimming and random nucleotide (N) region additions which occur during the V-(D)-J rearrangements (PubMed:24387714)

The "TRDC Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about TRDC comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets

TRDD2 | TRDD3 | TRDMT1 | TRDN | TRDV1 | TRDV2 | TRDV3 | TRE-TTC10-1 | TRE-TTC3-1 | TRE-TTC9-1 | TREH | TREM1 | TREM2 | TREML1 | TREML2 | TREML3P | TREML4 | TREML5P | TRERF1 | TRERNA1 | TREX1 | TREX2 | TRF-GAA8-1 | TRG | TRG-AS1 | TRGC1 | TRGC2 | TRGJP1 | TRGV1 | TRGV10 | TRGV2 | TRGV3 | TRGV4 | TRGV5 | TRGV5P | TRGV7 | TRGV9 | TRH | TRHDE | TRHDE-AS1 | TRHR | Triacylglycerol Lipase (TG Lipase) | TRIAP1 | TRIB1 | TRIB2 | TRIB3 | Tribbles homolog | Triggering receptor expressed on myeloid cells | TRIL | TRIM10 | TRIM11 | TRIM13 | TRIM14 | TRIM15 | TRIM16 | TRIM16L | TRIM17 | TRIM2 | TRIM21 | TRIM22 | TRIM23 | TRIM24 | TRIM25 | TRIM26 | TRIM27 | TRIM28 | TRIM29 | TRIM3 | TRIM31 | TRIM32 | TRIM33 | TRIM34 | TRIM35 | TRIM36 | TRIM37 | TRIM38 | TRIM39 | TRIM39-RPP21 | TRIM4 | TRIM40 | TRIM41 | TRIM42 | TRIM43 | TRIM43B | TRIM44 | TRIM45 | TRIM46 | TRIM47 | TRIM48 | TRIM49 | TRIM49B | TRIM49C | TRIM49D2 | TRIM5 | TRIM50 | TRIM51 | TRIM51EP | TRIM51G | TRIM51HP | TRIM52